Drug Trial Radar · NCT06758401
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
714
Planned (sponsor's estimate)
Start
Jul 23, 2025
Primary completion
Sep 5, 2028
Study completion Mar 1, 2029
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control. The study is seeking for participants who: * Are confirmed to have NSCLC (Stage 3 or 4). * Have PD-L1 levels in more than 50% of the cancer cells. All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) infusion (give directly into a vein). In addition, half of the participants will also receive Sigvotatug Vedotin once every 2 weeks as an IV infusion in addition to receiving pembrolizumab. Participants may receive pembrolizumab for up to about two years. Those participants taking Sigvotatug Vedotin can continue until their NSCLC is no longer responding. The study team will monitorsee how each participant is doing with the study treatment during regular visits at the clinic.
Conditions
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non-Small-Cell Lung (NSCLC)
Interventions
Sigvotatug VedotinDrug
MMAE-Antibody Drug Conjugate targeting Integrin Beta-6
PembrolizumabDrug
Anti-PD-(L)1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Baseline to date of death from any cause (Approximately 2 years).
- Progression Free Survival (PFS) assessed by blinded independent central review (BICR)Time frame: From Baseline to to date of first documentation of progression OR death (Approximately 2 years).
Locations
392 sites in 31 countries. Site status is shown where the registry gives one.
Fairbanks Cancer Care Physicians, PC
Fairbanks, Alaska · Not yet recruiting
Providence Medical Foundation
Fullerton, California · Recruiting
Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center
Fullerton, California · Recruiting
Providence St. Jude Medical Center
Fullerton, California · Recruiting
St. Jude Heritage Medical Group - Fullerton Plaza Multi-Specialty Clinic (Pulmonary Function Test)
Fullerton, California · Recruiting
Intermountain Health Cancer Center Lutheran Hospital
Golden, Colorado · Recruiting
Cancer Centers of Colorado St. Mary's Regional Hospital
Grand Junction, Colorado · Recruiting
Intermountain Health St. Mary's Regional Hospital
Grand Junction, Colorado · Recruiting
Intermountain Health
Grand Junction, Colorado · Recruiting
Intermountain Health Lutheran Hospital
Wheat Ridge, Colorado · Recruiting
Washington DC Veterans Affairs Medical Center
Washington D.C., District of Columbia · Recruiting
Mid Florida Hematology and Oncology Center
Orange City, Florida · Recruiting
BRCR Global
Plantation, Florida · Recruiting
Endeavor Health
Elmhurst, Illinois · Recruiting
Hope and Healing Cancer Services
Hinsdale, Illinois · Recruiting
Advocate Medical Group - Libertyville Oncology
Libertyville, Illinois · Recruiting
Endeavor Health
Naperville, Illinois · Recruiting
Hope and Healing Cancer Services
New Lenox, Illinois · Recruiting
Advocate Christ Medical Center
Oak Lawn, Illinois · Recruiting
Advocate Lutheran General Hospital
Park Ridge, Illinois · Recruiting
Saint Luke's South Hospital
Overland Park, Kansas · Recruiting
Maine Medical Center
Portland, Maine · Recruiting
MaineHealth Cancer Care and Blood Disorders Scarborough
Scarborough, Maine · Recruiting
MaineHealth Cancer Care and IV Therapy - South Portland
South Portland, Maine · Recruiting
Southcoast Centers for Cancer Care
Fairhaven, Massachusetts · Recruiting
Southcoast Centers for Cancer Care
Fall River, Massachusetts · Recruiting
Corewell Health - Butterworth Hospital
Grand Rapids, Michigan · Recruiting
Corewell Health - Lemmen Holton Cancer Pavilion
Grand Rapids, Michigan · Recruiting
Corewell Health - Research Specimen Processing Area
Grand Rapids, Michigan · Recruiting
Corewell Health Investigational Drug Services
Grand Rapids, Michigan · Recruiting
Corewell Health
Grand Rapids, Michigan · Recruiting
Minnesota Oncology Hematology, PA
Burnsville, Minnesota · Recruiting
Minnesota Oncology Hematology PA
Coon Rapids, Minnesota · Recruiting
M Health Fairview Cancer Clinic-Edina
Edina, Minnesota · Recruiting
Minnesota Oncology Hematology PA
Edina, Minnesota · Recruiting
Minnesota Oncology Hematology PA
Maple Grove, Minnesota · Recruiting
M Health Fairview St. John's Hospital
Maplewood, Minnesota · Recruiting
Minnesota Oncology Hematology PA
Maplewood, Minnesota · Recruiting
Hennepin County Medical Center
Minneapolis, Minnesota · Recruiting
North Memorial Health Cancer Center
Robbinsdale, Minnesota · Recruiting
Showing 40 of 392 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.